Cellular Immunity in Adolescents and Adults Following Acellular Pertussis Vaccine Administration

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2007 Feb 3

PMID 17267589

Citations 11

Authors

Claudius U Meyer

Fred Zepp

Michael Decker

Martin Lee

Swei-Ju Chang

Joel Ward

Sandra Yoder

Hugues Bogaert

Kathryn M Edwards

Affiliations

Soon will be listed here.

Abstract

Cell-mediated immune (CMI) responses to an acellular pertussis vaccine administered to 49 subjects, a subset of participants in the National Institutes of Health-funded adult acellular pertussis vaccine efficacy trial, were evaluated and compared with antibody responses to vaccine antigens. Levels of proliferation of and cytokine secretion from lymphocytes cultured in the presence of pertussis toxin, filamentous hemagglutinin, or pertactin were measured before vaccination and 1 month and 1 year after vaccination. Statistically significant increases in lymphocyte stimulation indices and cytokine secretion were noted at both 1 month and 1 year after vaccination. Brisk pertussis antigen-specific immunoglobulin G responses were also noted at 1 month after vaccination, but these responses had declined by nearly 50% at 1 year after vaccination. These studies clearly demonstrate that both cellular and humoral immune responses occur after the administration of acellular pertussis vaccines to adolescents and adults but that the CMI responses are of greater magnitude and longer duration. CMI responses may be a better correlate of long-term protection.

Citing Articles

Principles in Immunology for the Design and Development of Vaccines.

Meyer C, Zepp F Methods Mol Biol. 2021; 2410:27-56.

PMID: 34914041 DOI: 10.1007/978-1-0716-1884-4_2.

A multi-country, multi-year, meta-analytic evaluation of the sex differences in age-specific pertussis incidence rates.

Peer V, Schwartz N, Green M PLoS One. 2020; 15(4):e0231570.

PMID: 32324790 PMC: 7179848. DOI: 10.1371/journal.pone.0231570.

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations.

Juergens C, Trammel J, Shoji Y, Patterson S, Watson W, Webber C Hum Vaccin Immunother. 2018; 14(8):1948-1956.

PMID: 29543583 PMC: 6149808. DOI: 10.1080/21645515.2018.1452576.

Rediscovering Pertussis.

Zlamy M Front Pediatr. 2016; 4:52.

PMID: 27376050 PMC: 4896922. DOI: 10.3389/fped.2016.00052.

Polymorphism of IL-10 gene promoter region: association with T cell proliferative responses after acellular pertussis vaccination in adults.

Grondahl-Yli-Hannuksela K, Vahlberg T, Ilonen J, Mertsola J, He Q Immunogenetics. 2016; 68(9):733-41.

PMID: 27282930 DOI: 10.1007/s00251-016-0923-0.

References

Ward J, Cherry J, Chang S, Partridge S, Lee H, Treanor J . Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005; 353(15):1555-63. DOI: 10.1056/NEJMoa050824. View

Deen J, Mink C, Cherry J, Christenson P, Pineda E, Lewis K . Household contact study of Bordetella pertussis infections. Clin Infect Dis. 1995; 21(5):1211-9. DOI: 10.1093/clinids/21.5.1211. View

Ward J, Cherry J, Chang S, Partridge S, Keitel W, Edwards K . Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis. 2006; 43(2):151-7. DOI: 10.1086/504803. View

McHeyzer-Williams L, Malherbe L, McHeyzer-Williams M . Checkpoints in memory B-cell evolution. Immunol Rev. 2006; 211:255-68. DOI: 10.1111/j.0105-2896.2006.00397.x. View

Zepp F, Knuf M, Habermehl P, Schmitt J, Rebsch C, Schmidtke P . Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun. 1996; 64(10):4078-84. PMC: 174340. DOI: 10.1128/iai.64.10.4078-4084.1996. View

Zepp F, Knuf M, Habermehl P, Schmitt H, Meyer C, Clemens R . Cell-mediated immunity after pertussis vaccination and after natural infection. Dev Biol Stand. 1997; 89:307-14. View

Mills K, Ryan M, Ryan E, Mahon B . A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun. 1998; 66(2):594-602. PMC: 107945. DOI: 10.1128/IAI.66.2.594-602.1998. View

Ausiello C, Lande R, la Sala A, Urbani F, Cassone A . Cell-mediated immune response of healthy adults to Bordetella pertussis vaccine antigens. J Infect Dis. 1998; 178(2):466-70. DOI: 10.1086/515628. View

Minh N, Edelman K, He Q, Viljanen M, Arvilommi H, Mertsola J . Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children. Vaccine. 1998; 16(17):1604-10. DOI: 10.1016/s0264-410x(98)00072-3. View

10.

Ausiello C, Lande R, Urbani F, la Sala A, Stefanelli P, Salmaso S . Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun. 1999; 67(8):4064-71. PMC: 96703. DOI: 10.1128/IAI.67.8.4064-4071.1999. View

11.

Cherry J, Chang S, Klein D, Lee M, Barenkamp S, Bernstein D . Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis. 2004; 39(11):1715-8. DOI: 10.1086/425003. View

12.

Minh N, He Q, Edelman K, Putto-Laurila A, Arvilommi H, Viljanen M . Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults. Vaccine. 2000; 18(19):1971-4. DOI: 10.1016/s0264-410x(99)00534-4. View

13.

Leef M, Elkins K, Barbic J, Shahin R . Protective immunity to Bordetella pertussis requires both B cells and CD4(+) T cells for key functions other than specific antibody production. J Exp Med. 2000; 191(11):1841-52. PMC: 2213518. DOI: 10.1084/jem.191.11.1841. View

14.

Ausiello C, Lande R, Urbani F, Di Carlo B, Stefanelli P, Salmaso S . Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis. 2000; 181(6):1989-95. DOI: 10.1086/315509. View

15.

Mahon B, Brady M, Mills K . Protection against Bordetella pertussis in mice in the absence of detectable circulating antibody: implications for long-term immunity in children. J Infect Dis. 2000; 181(6):2087-91. DOI: 10.1086/315527. View

16.

Hodder S, Cherry J, MORTIMER Jr E, Ford A, Gornbein J, Papp K . Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis. 2000; 31(1):7-14. DOI: 10.1086/313913. View

17.

Cassone A, Mastrantonio P, Ausiello C . Are only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients?. J Infect Dis. 2000; 182(5):1575-7. DOI: 10.1086/315898. View

18.

Schaeffer L, Weiss A . Pertussis toxin and lipopolysaccharide influence phagocytosis of Bordetella pertussis by human monocytes. Infect Immun. 2001; 69(12):7635-41. PMC: 98857. DOI: 10.1128/IAI.69.12.7635-7641.2001. View

19.

Mascart F, Verscheure V, Malfroot A, Hainaut M, Pierard D, Temerman S . Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J Immunol. 2003; 170(3):1504-9. DOI: 10.4049/jimmunol.170.3.1504. View

20.

Le T, Cherry J, Chang S, Knoll M, Lee M, Barenkamp S . Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis. 2004; 190(3):535-44. DOI: 10.1086/422035. View